Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

We have investigated the biological and therapeutic properties of a humanized anti-CD4 MoAb, hIgG1-CD4, in patients with refractory psoriasis and rheumatoid arthritis (RA). hIgG1-CD4 is a modulating, non-depleting MoAb, which induced a first-dose reaction in most patients treated. It provided brief symptomatic relief in both conditions, and psoriasis appeared easier to control with conventional agents after MoAb therapy. At the doses used, hIgG1-CD4 did not synergize therapeutically with the panlymphocyte MoAb CAMPATH-1H (C1H) in patients with RA treated sequentially with both agents. There were no serious adverse effects definitely attributable to therapy. Our results are compared with those of other CD4 MoAb studies, and factors influencing the outcome of therapy are discussed.

Original publication

DOI

10.1111/j.1365-2249.1997.tb08312.x

Type

Journal article

Journal

Clin Exp Immunol

Publication Date

11/1997

Volume

110

Pages

158 - 166

Keywords

Adolescent, Adult, Aged, Animals, Antibodies, Bispecific, Antibodies, Monoclonal, Arthritis, Rheumatoid, Autoimmune Diseases, CD4 Antigens, Female, Humans, Immunotherapy, Male, Middle Aged, Psoriasis, Rats